Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.

AIMS: To report the incidence of infectious and noninfectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor (VEGF) from a multicenter clinical trial in Japan. METHODS: A retrospective multicenter review of the data of patients who received intravitreal anti-VEGF injections between January 2007 and March 2011 was undertaken. Cases with the clinical diagnosis of endophthalmitis resulting from intravitreal injection were identified and reviewed. RESULTS: A total of 5,236 intravitreal anti-VEGF injections (1,209 intravitreal injections of bevacizumab, 3,827 injections of ranibizumab, and 200 injections of pegaptanib sodium) had been administered. Five patients (0.095%), all of whom had received bevacizumab, were diagnosed as having endophthalmitis after the intravitreal injection. All patients visited the institutes for re-examination within 1-2 days after the injection. Among the 5 patients, 2 (0.038%) were culture positive for Streptococcus oralis and Enterococcus faecalis, respectively. The remaining 3 eyes (0.057%) developed presumed noninfectious endophthalmitis. CONCLUSION: Although endophthalmitis is a rare complication associated with intravitreal injection, in this series intravitreal anti-VEGF injection caused infectious or noninfectious endophthalmitis at a relatively high frequency. Further investigations are needed to consider an appropriate injection protocol for minimizing the incidence rates of endophthalmitis, and to assess the optimal treatment protocol for intravitreal injection-related endophthalmitis although it was difficult to differentiate these two entities.

A new non-trocar system for 25-gauge transconjunctival pars plana vitrectomy.

PURPOSE: To introduce a new non-trocar system for 25-gauge transconjunctival pars plana vitrectomy (PPV). DESIGN: Study of a new surgical instrument. METHODS: This new non-trocar system for 25-gauge transconjunctival PPV consists of a contact lens ring featuring four projections containing 1.0-mm diameter holes located 3.0 mm from the ring edge, a wedge-shaped 25-gauge infusion cannula, and two plugs. RESULTS: The ring is fixed with 7-0 silk sutures at the 3- and 9-o'clock positions on the limbus. Using the 25-gauge needle, three conjunctival and scleral incisions (n = 3) are made at the projection holes located inferotemporally, superonasally, and superotemporally. No intra- or postoperative complications were encountered in 14 patients treated by this non-trocar 25-gauge transconjunctival PPV. CONCLUSION: Using the system introduced here, 25-gauge transconjunctival PPV can be performed without suturing sclerotomies and without intra- or postoperative complications.

[Low power transpupillary thermotherapy of choroidal neovascularization].

PURPOSE: To assess the effectiveness of low power transpupillary thermotherapy (TTT) for choroidal neovascularization (CNV). METHOD: We performed TTT on 55 eyes of 55 patients with subretinal CNV between April 2001 and December 2002, and observed them after therapy for more than 6 months. The laser power ranged from 80 to 320 mW when the spot size was 3 mm. We evaluated visual acuity, subretinal fluid (SRF), and CNV size. RESULTS: Visual acuity improved by 2 lines or more in 16 eyes (29%), was unchanged in 19 eyes (35%), and decreased in 20 eyes (36%). SRF decreased in 30 eyes (54%), was unchanged in 13 eyes (24%), and increased in 12 eyes (22%). CNV diminished in 33 eyes (60%), was unchanged in 10 eyes (18%), and became enlarged in 12 eyes (22%). CONCLUSIONS: Low power TTT can be an effective treatment for subgroups of patients with subfoveal CNV.